Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older.
- People who have been diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma, confirmed through a tissue or cell sample.
- People whose cancer has spread to nearby areas or to other parts of the body.
- People who have at least one measurable area of cancer in the abdomen that is 1 centimeter or larger, as measured by standard imaging guidelines.
- People who are reasonably able to carry out daily activities, as assessed by a standard medical scale (confirm with trial site for exact score requirements).
- People who have or have had another type of cancer, as long as that cancer or its treatment is unlikely to affect this study's safety or results.
- People who are able to understand the study and are willing to sign a consent form.
Who may not be able to join:
- People who are unable or unwilling to have an MRI scan, including those with certain medical devices such as a cardiac pacemaker or certain types of brain clips that are not compatible with MRI.
- People with poorly controlled high blood pressure (systolic above 170 or diastolic above 110), although blood pressure medication may be used to bring levels within range before eligibility is assessed.
- People with moderate to severe heart failure (classified as Class III or higher on a standard medical scale).
- People who are pregnant, as the study drug may carry an unknown risk to an unborn child.
- People who are capable of becoming pregnant and are not willing to take a urine pregnancy test before taking part in the study scans.
- People who are breastfeeding or chestfeeding, as the study drug may carry an unknown risk to a nursing child.
- People with a known allergy to the study substance (HP 13C pyruvate) or any of its ingredients.
- People whose personal circumstances or health conditions, in the opinion of the study doctor, would make it difficult to follow the study procedures.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zhen Wang, MD, University of California, San Francisco
Phone: (415) 502-1822
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of participants with best objective response (Cohorts A and B); Mean percent change in target tumor peak HP 13C lactate/pyruvate ratio over time; Mean change in target tumor HP 13C lactate/pyruvate area under the curve (AUC) ratio over time; Mean percent change in target tumor HP 13C pyruvate to lactate conversion rate (kPL).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.